A Phase 1b Study to Test the Safety, Pharmacokinetics, & Pharmacodynamics of a Novel NLRP3 Inflammasome Inhibitor in Early- Stage Parkinson’s Disease

Time: 9:00 am
day: Day Two


  • Hear about the first study of Selnoflast in participants with early idiopathic PD
  • Characterizing a new compound targeting NLRP3 inflammasome
  • Exploring innovative Ph1b design to test safety, pharmacokinetics and pharmacodynamics